Key Points
- Director Ronald Todd Plott purchased 15,000 Phio Pharmaceuticals shares at an average price of $1.14, investing $17,100 and becoming the direct owner of 15,000 shares.
- PHIO shares were trading at $1.21, up 5.2%, with a market capitalization of approximately $14.06 million. The company reported a quarterly loss of $0.36 per share, in line with analyst expectations.
- Geode Capital Management increased its stake by 38.7%, while institutional investors collectively held 57.31% of the stock. Analyst sentiment remained mixed, with one Buy and one Sell rating producing an overall “Hold” consensus.
Phio Pharmaceuticals Corp. (NASDAQ:PHIO - Get Free Report) Director Ronald Todd Plott acquired 15,000 shares of the stock in a transaction on Wednesday, August 19th. The stock was purchased at an average cost of $1.14 per share, with a total value of $17,100.00. Following the transaction, the director directly owned 15,000 shares of the company's stock, valued at $17,100. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Phio Pharmaceuticals Trading Up 5.2%
PHIO opened at $1.21 on Friday. The company has a fifty day simple moving average of $1.04 and a 200 day simple moving average of $1.12. The firm has a market cap of $14.06 million, a price-to-earnings ratio of -0.94 and a beta of 0.82. Phio Pharmaceuticals Corp. has a twelve month low of $0.81 and a twelve month high of $4.19.
Phio Pharmaceuticals (NASDAQ:PHIO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, hitting analysts' consensus estimates of ($0.36). On average, analysts forecast that Phio Pharmaceuticals Corp. will post -1.41 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC boosted its holdings in Phio Pharmaceuticals Corp. (NASDAQ:PHIO - Free Report) by 38.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,694 shares of the company's stock after purchasing an additional 16,108 shares during the quarter. Geode Capital Management LLC owned approximately 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 57.31% of the company's stock.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a "sell (e+)" rating on shares of Phio Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $14.00.
Read Our Latest Report on Phio Pharmaceuticals
About Phio Pharmaceuticals
(
Get Free Report)
Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company's core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.
Phio's TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
